Delcath Systems, Inc.
DCTH
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinicaā¦ read more
Healthcare
Medical Devices
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$12.22
Price+1.50%
$0.18
1Y
Price
Market Cap
$421.855m
Small
Price/Earnings 3y Avg5y Avg
1,222x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+2.3%
EBITDA Margin+4.0%
Net Profit Margin+21.0%
Free Cash Flow Margin+2.3%
EBITDA Margin+4.0%
Net Profit Margin+21.0%
Free Cash Flow MarginRevenue
$90.441m
+114.0%
1y CAGR+597.2%
3y CAGR+442.0%
5y CAGREarnings
$561k
+104.5%
1y CAGR+39.5%
3y CAGR+19.1%
5y CAGREPS
$0.01
+101.1%
1y CAGR+66.0%
3y CAGR+45.8%
5y CAGRBook Value
$112.710m
$124.838m
Assets$12.128m
Liabilities$907k
DebtDebt to Assets
0.7%
0.1x
Debt to EBITDAFree Cash Flow
$19.193m
+162.6%
1y CAGR+58.9%
3y CAGR+41.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company